Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd share price declined by 3.34% to Rs 617.0. The Company's net profit saw a strong growth of 45.54% to Rs 1.63 crore, while revenue from operations increased sharply by 62.19% to Rs 23.29 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.66 lakh crore, easing 4.55%. It has inched up 4.66% over last one week and gained upto 1.10% in last one month while the market capitalization of Shree Ganesh Remedies Ltd has slipped by 2.13% and 0.88% in the same period respectively. Profit before tax (PBT) of Shree Ganesh Remedies Ltd stood at Rs 2.26 crore in Q3 FY26, nosediving by 66.32% year-on-year, and jumping 47.71% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 71.78% YoY and gaining 4.56% sequentially. Total expenses surged 62.53% to Rs 21.86 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 13.8 crore, surging by 64.29% YoY, while employee benefits expense was at Rs 3.13 crore, inching up 6.83% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 0.64% to Rs 109.29 crore, while net profit tanked by 23.02% to Rs 17.76 crore, compared to previous TTM. EBITDA surged by 3539% to Rs 31.99 crore, and PBT tumbled by 23.22% to Rs 24.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 0.0 crore in FY26, as against Rs 0.0 crore in FY25. Shree Ganesh Remedies Ltd soared by 23.45% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 11.78% during the same period.

Shree Ganesh Remedies Ltd share price declined by 3.34% to Rs 617.0. The Company's net profit jumped 45.54% to Rs 1.63 crore, while revenue from operations increased sharply by 62.19% to Rs 23.29 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.52%. It has inched up 6.57% over last one week and moved up slightly by 1.39% in last one month while the market capitalization of Shree Ganesh Remedies Ltd has slipped by 1.39% and 2.34% in the same period respectively. Profit before tax (PBT) of Shree Ganesh Remedies Ltd stood at Rs 2.26 crore in Q3 FY26, nosediving by 66.32% year-on-year, and surging by 47.71% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 71.78% YoY and easing 4.56% sequentially. Total expenses soared by 62.53% to Rs 21.86 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 13.8 crore, soaring by 64.29% YoY, while employee benefits expense was at Rs 3.13 crore, inching up 6.83% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 0.64% to Rs 109.29 crore, while net profit plunged by 23.02% to Rs 17.76 crore, compared to previous TTM. EBITDA jumped by 3539% to Rs 31.99 crore, and PBT collapsed by 23.22% to Rs 24.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 0.0 crore in FY26, as against Rs 0.0 crore in FY25. Shree Ganesh Remedies Ltd rallied 23.45% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 11.78% during the same period.

Shree Ganesh Remedies Limited will hold a board meeting on Saturday, October 31, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited. The company’s trading window for share transactions was closed from October 1, 2026, and will remain closed until 48 hours after the financial results are declared.

Shree Ganesh Remedies Limited submitted a certificate to the BSE Limited, confirming that Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 is not applicable for the quarter ended September 30, 2026, as all shares are held in demat form and no rematerialisation requests were received, according to a confirmation from Bigshare Services Private Limited.

Shree Ganesh Remedies Limited will close its trading window for securities transactions from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half-year ended September 30, 2026, in compliance with Securities and Exchange Board of India regulations.

Shree Ganesh Remedies Ltd share price ticked higher by 2.42% to Rs 621.15. The Company's net profit tumbled by 82.14% to Rs 1.12 crore, while revenue from operations nosedived 56.75% to Rs 14.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, easing 4.31%. It has improved by 0.98% over last one week and climbed by 11.49% in last one month while the market capitalization of Shree Ganesh Remedies Ltd has softened by 5.56% and 22.40% in the same period respectively. Profit before tax (PBT) of Shree Ganesh Remedies Ltd stood at Rs 1.53 crore in Q2 FY26, nosediving by 66.74% year-on-year, and tanking 82.45% quarter-on-quarter. EBITDA came in at Rs 2 crore, tumbling by 63.70% YoY and plunging by 76.74% sequentially. Total expenses slumped by 45.37% to Rs 13.45 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 8.4 crore, registering a fall of 23.84% YoY, while employee benefits expense was at Rs 2.93 crore, ticking higher by 2.09% YoY. For the TTM ended FY26, revenue from operations dropped by 13.74% to Rs 108.6 crore, while net profit fell 17.93% to Rs 23.07 crore, compared to previous TTM. EBITDA soared by 4120% to Rs 35.49 crore, and PBT contracted 18.06% to Rs 31.27 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 0.0 crore in FY26, as against Rs 30.45 crore in FY25. Shree Ganesh Remedies Ltd rallied 18.39% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Shree Ganesh Remedies Limited will hold a board meeting on Wednesday, August 12, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing. The company’s trading window for share transactions was closed from July 1, 2026, and will remain closed for 48 hours after the financial results are made public.

Net profit of Shree Ganesh Remedies declined 4.86% to Rs 6.27 crore in the quarter ended March 2026 as against Rs 6.59 crore during the previous quarter ended March 2025. Sales rose 35.90% to Rs 33.20 crore in the quarter ended March 2026 as against Rs 24.43 crore during the previous quarter ended March 2025. For the full year,net profit declined 23.02% to Rs 17.76 crore in the year ended March 2026 as against Rs 23.07 crore during the previous year ended March 2025. Sales rose 0.64% to Rs 109.29 crore in the year ended March 2026 as against Rs 108.60 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales33.2024.43 36 109.29108.60 1 OPM %34.2840.40 -32.0436.10 - PBDT11.5211.20 3 34.4940.83 -16 PBT8.728.77 -1 24.0131.27 -23 NP6.276.59 -5 17.7623.07 -23 Powered by Capital Market - Live

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Shree Ganesh Remedies Ltd rose 3.78% today to trade at Rs 535. The BSE Healthcare index is up 0.27% to quote at 43607.96. The index is up 4.13 % over last one month. Among the other constituents of the index, Themis Medicare Ltd increased 2.49% and Dr Reddys Laboratories Ltd added 2.31% on the day. The BSE Healthcare index went up 2.14 % over last one year compared to the 2.79% fall in benchmark SENSEX. Shree Ganesh Remedies Ltd has added 11.02% over last one month compared to 4.13% gain in BSE Healthcare index and 5.15% rise in the SENSEX. On the BSE, 900 shares were traded in the counter so far compared with average daily volumes of 5550 shares in the past one month. The stock hit a record high of Rs 828 on 23 Apr 2025. The stock hit a 52-week low of Rs 381.1 on 27 Jan 2026.